649 related articles for article (PubMed ID: 15928338)
21. [Diabetes and hypertension].
Sayk F; Iwen KA; Lehnert H
Dtsch Med Wochenschr; 2009 Nov; 134(45):2296-301. PubMed ID: 19876807
[TBL] [Abstract][Full Text] [Related]
22. Microalbuminuria in essential hypertension.
Crippa G
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S74-7. PubMed ID: 11986900
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus.
Rosner MH; Okusa MD
Arch Intern Med; 2003 May; 163(9):1025-9. PubMed ID: 12742799
[TBL] [Abstract][Full Text] [Related]
24. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
25. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
Luño J; Valderrábano F
An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
[No Abstract] [Full Text] [Related]
26. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
27. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
Tocci G; Sciarretta S; Facciolo C; Volpe M
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
[TBL] [Abstract][Full Text] [Related]
28. [Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].
Schmieder RE; Schrader J; Zidek W; Tebbe U; Bramlage P; Paar WD; Böhm M
Dtsch Med Wochenschr; 2006 Nov; 131(47):2665-71. PubMed ID: 17109277
[No Abstract] [Full Text] [Related]
29. [Is microalbuminuria, an early marker of clinical nephropathy, also a cardiovascular risk factor?].
Raynaud E; Brun JF; Fédou C; Puech-Cathala AM; Pérez-Martin A; Orsetti A
Ann Biol Clin (Paris); 1998; 56(6):671-9. PubMed ID: 9853026
[TBL] [Abstract][Full Text] [Related]
30. Influence of microalbuminuria in achieving blood pressure goals.
Duka I; Bakris G
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):457-63. PubMed ID: 18695385
[TBL] [Abstract][Full Text] [Related]
31. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade.
Menne J; Chatzikyrkou C; Haller H
J Hypertens; 2010 Oct; 28(10):1983-94. PubMed ID: 20634721
[TBL] [Abstract][Full Text] [Related]
32. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
Björck S; Aurell M
J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
[TBL] [Abstract][Full Text] [Related]
34. Diabetic nephropathy: implications for renal and cardiovascular outcomes.
Folan LA; Tuttle KR
Minerva Med; 2004 Oct; 95(5):385-94. PubMed ID: 15467514
[TBL] [Abstract][Full Text] [Related]
35. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
[TBL] [Abstract][Full Text] [Related]
36. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
Basi S; Lewis JB
Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
Weber MA; Giles TD
Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
[TBL] [Abstract][Full Text] [Related]
38. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"].
Tislér A
Orv Hetil; 2003 May; 144(18 Suppl 1):898-901. PubMed ID: 12785234
[TBL] [Abstract][Full Text] [Related]
39. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.
Montalescot G; Collet JP
Eur Heart J; 2005 Dec; 26(24):2616-22. PubMed ID: 16006442
[TBL] [Abstract][Full Text] [Related]
40. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
